ArticleScientific reports2025
Cost effectiveness of first line nivolumab plus bevacizumab and chemotherapy for advanced non squamous non small cell lung cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cost-effectiveness of nivolumab plus bevacizumab and chemotherapy for patients with advanced non-squamous non-small-cell lung-cancer (NSCLC) was uncleared yet. The current analysis aimed to evaluate the cost-effectiveness of nivolumab plus bevacizumab and chemotherapy compared with bevacizumab plus chemotherapy for patients with untreated non-squamous NSCLC in Chinese context. A partitioned survival model that simulated 3-week patients transition in 20-year time horizon was conducted to evaluate the economic value. The clinical data were obtained from TASUKI-52 trial, cost and utility values were gathered from the local charges and previously published studies. Sensitivity analyses were conducted to examine the robustness of the model results when parameters changed, subgroup analyses were also conducted to enhance the comprehensiveness of the analysis. Nivolumab plus bevacizumab and chemotherapy yielded an additional 0.90 QALYs with the marginal cost of $231,948.33, resulting in the incremental cost-effectiveness ratio (ICER) of $256,791.53 per additional quality-adjusted life-years (QALYs) gained, which higher than the Chinese willingness-to-pay (WTP) threshold of $39,057/QALY. Sensitivity analyses confirmed the robustness of the model outcomes. Subgroup analyses revealed that nivolumab plus bevacizumab and chemotherapy was unlikely to be the cost-effective option for all subgroups due to the unfavorable ICERs. Nivolumab plus bevacizumab and chemotherapy was unlikely to be the cost-effective first-line therapy for untreated advanced non-squamous NSCLC patients compared with bevacizumab plus chemotherapy from the perspective of Chinese health-care system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.